Clinical trial

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

NCT06475508

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention Complarate® Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Actemra® Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Comparison of Complarate® (Tocilizumab Biosimilar) and Actemra® in Patients With Rheumatoid Arthritis

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2023-02-13

PhasePHASE3

Conditions

Rheumatoid Arthritisverified · MONDO: rheumatoid arthritis

Interventions

Complarate®BIOLOGICAL

Actemra®BIOLOGICAL

Sponsors & collaborators

AO GENERIUMlead sponsor

Mapped research locations

MoscowRussia6 Saint PetersburgRussia6 YaroslavlRussia3 NovosibirskRussia2 SaratovRussia1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06475508 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.